Cytovation Announces Dosing of First Patient in its Phase I/II CICILIA Trial Investigating CyPep-1 in Patients with Solid Cancers
Bergen, May 29th 2020 – CyPep-1 is a novel lytic immunotherapy that both selectively binds and destroys tumor cells and promotes an anti-tumor immune response. Bergen, Norway, and Schiphol, the Netherlands (May 26, 2020) – Cytovation AS (“Cytovation”), a clinical-stage biotechnology company focused on developing CyPep-1, a next-generation lytic immunotherapy, is pleased to announce that the first patient has today been successfully dosed in its Phase I/II CICILIA clinical trial. The CICILIA trial will investigate CyPep-1 in patients with advanced solid cancers (ClinicalTrials.gov Identifier: NCT04260529).
Read more on LinkedIn or download article as PDF.